Healthcare >> CEO Interviews >> October 12, 2001
RICHARD PALMER joined Alizyme Plc as Chief Operating Officer in
September 1996. In March 1997 he was appointed Chief Executive Officer
while retaining responsibility for the company's portfolio as Director
of R&D. Dr Palmer has held various positions in research and development
management in Wellcome and Glaxo Wellcome. He spent approximately 20
years in research in Wellcome, establishing an international reputation
for his work. He has published over 100 research papers and is in the
top 10 cited biomedical scientists in the UK from his work on the
discovery and role of nitric oxide in physiology and pathophysiology. In
1992, he moved into development management, becoming responsible for
Wellcome's portfolio of biotechnology projects, before becoming Director
of International Oncology Planning in Glaxo Wellcome in 1995. Dr Palmer
obtained his BSc in Applied Biology from the University of Bath and a
PhD in Pharmacology from University College, London. Profile
of Alizyme Plc?
Dr. Palmer: Alizyme was founded in 1995 as a company to license-in early
stage products, develop them,
